Skip to main content

Health condition · Clinically reviewed

Myelodysplastic syndrome, from risk score to the right treatment path.

A bone marrow disorder where risk varies enormously between people. Getting the IPSS-R score right shapes everything that follows.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, British Society for Haematology and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including IPSS-R risk stratification, azacitidine and stem cell transplant pathways.

Key facts

Myelodysplastic syndrome at a glance.

The essentials, in plain English - what it is, how risk is judged, and how it's treated in the UK today.

  • What it is

    A group of bone marrow disorders where blood-forming stem cells produce abnormal, poorly-functioning blood cells.

  • Risk of progression

    A "pre-leukaemic" condition - some people progress to acute myeloid leukaemia, others live for years with stable low-risk disease.

  • Who it affects

    Mostly older adults - often diagnosed incidentally on a routine blood test, sometimes after unexplained tiredness.

  • Risk scoring

    IPSS-R - a validated score combining blood counts, cytogenetics and marrow blast percentage - guides every treatment decision.

  • Low-risk approach

    Watchful waiting and supportive care - transfusions and growth factors - often without disease-modifying drugs.

  • Only cure

    Allogeneic stem cell transplant is the sole potentially curative option, reserved for fit, eligible higher-risk patients.

Why this guide matters

Risk-stratified care, not a single script.

MDS covers a huge range of severity. The three points below explain why treatment looks so different from one patient to the next.

  • Risk drives everything

    The IPSS-R score - not the diagnosis alone - determines whether watchful waiting or active treatment is right.

  • Supportive care is real treatment

    Transfusions, growth factors and infection prevention meaningfully extend and improve life in low-risk disease.

  • Transplant is time-sensitive

    For eligible higher-risk patients, earlier referral for stem cell transplant assessment keeps the curative option open.

How the diagnosis is made

From an abnormal blood count to a clear risk score.

The steps a UK haematology team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Full blood count and film

    Cytopenias - low haemoglobin, neutrophils or platelets - plus dysplastic features seen on the blood film often trigger the first suspicion.

  2. 02

    Assessing

    Exclude other causes

    Vitamin B12, folate and iron studies, plus a medication and alcohol history, to rule out reversible causes of cytopenia before assuming marrow disease.

  3. 03

    Assessing

    Specialist haematology referral

    Persistent unexplained cytopenia is referred to a commissioned specialist haematology service for further work-up.

  4. 04

    Confirming

    Bone marrow aspirate and biopsy

    The key diagnostic test - looks directly at dysplastic changes across the myeloid, erythroid and megakaryocyte lineages, and counts blast cells.

  5. 05

    Confirming

    Cytogenetics and molecular testing

    Chromosomal analysis and mutation panels identify prognostic markers, including deletion 5q, which changes treatment options.

  6. 06

    Planning

    IPSS-R risk stratification

    Blood counts, marrow blast percentage and cytogenetic risk are combined into a validated score - very low to very high - that shapes the whole treatment plan.

  7. 07

    Planning

    MDT treatment planning

    A specialist haematology multidisciplinary team, including transplant physicians where relevant, agrees the risk-adapted management plan with you.

Typical timeline: an abnormal blood test to a full risk-adapted plan within a few weeks.

Symptoms

What myelodysplastic syndrome actually feels like.

Most symptoms come from low blood counts - anaemia, low neutrophils and low platelets. And the features that mean it's time to escalate.

  • Fatigue and breathlessness

    The most common presenting symptoms - driven by anaemia from reduced red cell production.

  • Recurrent infections

    Low neutrophil counts (neutropenia) mean infections come more often and can be harder to shift.

  • Easy bruising and bleeding

    Low platelet counts (thrombocytopenia) cause bruising, nosebleeds or bleeding gums.

  • Pallor

    Visible paleness of the skin and inner eyelids, reflecting significant anaemia.

  • Incidental finding

    Many cases are picked up on a routine blood test in someone who otherwise feels well.

  • Weight loss and night sweats

    Less common but worth flagging - can suggest more active or higher-risk disease.

  • Splenomegaly

    An enlarged spleen occurs in some subtypes and is checked for on examination.

  • Red flag - rapidly worsening counts

    A fast fall in blood counts or new blasts in the blood can signal progression to acute leukaemia and needs urgent review.

Treatment

How myelodysplastic syndrome is treated in the UK.

Supportive care first for low-risk disease, disease-modifying therapy for higher-risk disease - and transplant where it's a realistic, curative option.

  • Watchful waiting

    For low-risk disease with mild or no symptoms - regular blood count monitoring without active treatment.

  • Red cell transfusions

    Supportive care for symptomatic anaemia - the mainstay of low-risk disease management for many patients.

  • Platelet transfusions

    Used for significant bleeding or very low platelet counts, particularly around procedures.

  • Growth factors

    Erythropoietin-stimulating agents can reduce transfusion needs in selected lower-risk patients.

  • Azacitidine

    A hypomethylating agent and the standard disease-modifying therapy for higher-risk MDS.

  • Lenalidomide

    Particularly effective in MDS with deletion 5q - can restore normal blood counts in this specific subgroup.

  • Iron chelation

    For patients who become transfusion-dependent, to prevent organ damage from iron overload over time.

  • Allogeneic stem cell transplant

    The only potentially curative option - offered to eligible, generally fitter higher-risk patients after specialist assessment.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematology team knows your bloods, marrow findings and risk score, and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Suspected cancer: recognition and referral (NG12) - haematological cancers.

  • British Society for Haematology. Guidelines for the diagnosis and management of adult myelodysplastic syndromes.

  • European LeukemiaNet. Recommendations for the management of MDS.

  • NHS England. Specialist commissioning standards for haemato-oncology services.

Red flags

When MDS needs urgent attention.

Most MDS is monitored steadily in outpatient clinics. These are the situations that aren't routine - and where urgent review is needed.

  • Rapidly falling blood counts

    A fast drop in haemoglobin, neutrophils or platelets over days to weeks needs urgent haematology review.

  • Circulating blast cells

    Blasts appearing in the peripheral blood can signal transformation towards acute myeloid leukaemia.

  • Fever with neutropenia

    Neutropenic sepsis is a medical emergency - fever in someone with known low neutrophils needs immediate hospital assessment.

  • Significant or spontaneous bleeding

    Unexplained bruising, gum bleeding or nosebleeds beyond the usual pattern warrant urgent platelet and coagulation review.

  • New breathlessness at rest

    Severe symptomatic anaemia causing breathlessness at rest may need urgent transfusion.

  • Iron overload symptoms

    Fatigue, joint pain or new organ dysfunction in a transfusion-dependent patient should prompt a chelation review.

  • Failure to respond to transfusions

    Reduced response to red cell or platelet transfusions can indicate disease progression or alloimmunisation.

  • New splenomegaly or lymphadenopathy

    New organ enlargement can suggest a more proliferative or transforming disease process.

  • Missed monitoring appointments

    MDS is monitored closely - missed blood count checks risk a late catch of rapid deterioration.

Living with it

A variable condition, with a clear monitoring rhythm.

Four things that make the biggest difference day to day - regular monitoring, taking infection risk seriously, pacing fatigue and asking about transplant early.

A quiet reminder

Stable low-risk disease can stay stable for years.

Regular monitoring, not worry, is what catches change early and keeps the plan on track.

  1. 01 Monitor

    Keep every blood test appointment

    Regular monitoring is how low-risk disease stays low-risk for longer - even when you feel well.

  2. 02 Infection

    Take neutropenia seriously

    Report fevers promptly, keep up to date with vaccinations your team recommends, and avoid known infection risks.

  3. 03 Fatigue

    Pace your energy

    Anaemia-related fatigue is real and physical, not just tiredness - plan rest around your transfusion cycle.

  4. 04 Support

    Ask about transplant early

    If you are higher-risk and potentially transplant-eligible, an early specialist conversation keeps options open.

Frequently asked

Everything we get asked about MDS.

Quick answers on risk scoring, supportive care, drug therapy and stem cell transplant.

  • What is myelodysplastic syndrome?

    A group of bone marrow disorders in which blood-forming stem cells produce abnormal, poorly-functioning blood cells. It is sometimes called a "pre-leukaemic" condition because some forms carry a variable risk of progressing to acute myeloid leukaemia.

  • Is MDS a type of cancer?

    It is classified as a haematological malignancy and is managed by specialist cancer and haematology teams, though many people with low-risk disease live for years with a good quality of life on supportive care alone.

  • How is MDS diagnosed?

    A full blood count and blood film usually raise the first suspicion. Diagnosis is confirmed by a bone marrow aspirate and biopsy with cytogenetic testing, after other causes of cytopenia such as vitamin deficiency have been excluded.

  • What is the IPSS-R score?

    The Revised International Prognostic Scoring System combines blood counts, bone marrow blast percentage and cytogenetic findings into a risk category from very low to very high. It guides whether watchful waiting or active treatment is appropriate.

  • Can MDS be cured?

    Allogeneic stem cell transplant is the only potentially curative treatment, but it carries significant risks and is generally reserved for fitter, eligible patients with higher-risk disease. Most low-risk disease is managed with supportive care rather than aiming for cure.

  • What does azacitidine do?

    It is a hypomethylating agent used as standard disease-modifying therapy in higher-risk MDS, working to restore more normal blood cell production and delay progression to acute leukaemia.

Related content

Keep reading.